A Phase 1 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 92nd largest by enrollment, is one of 8 that started in 2023, is one of 12 in phase 1, and was the 15th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 113th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 40 in phase 1, and was the 26th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this cohort had a screening body weight (BW) of at least 50 kilograms (kg) received placebo administered subcutaneously (SC) once weekly (QW) during Weeks 1 to 8.
Drug: Placebo
Participants in this cohort had a screening body weight of at least 50 kg received 2.5 milligrams (mg) tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.
Drug: Tirzepatide
Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8.
Drug: Placebo
Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8.
Drug: Tirzepatide
Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8.
Drug: Placebo
Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Administered SC
Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.
Time frame: Baseline through Week 14
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide
PK: AUC0-tau of tirzepatide was reported.
Time frame: Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.
PK: Maximum Concentration (Cmax) of Tirzepatide
PK: Cmax of tirzepatide
Time frame: Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.
| Milestone | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) |
|---|---|---|---|---|---|---|
| Started | 3 | 6 | 2 | 7 | 3 | 7 |
| Received at least one dose of study drug | 2 | 6 | 2 | 7 | 3 | 7 |
| Completed | 2 | 5 | 2 | 6 | 3 | 6 |
| Not completed | 1 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 1 | 0 | 0 |
Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.
| Percentage of participants | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) |
|---|---|---|---|---|---|---|
| TEAE | 0.0 | 83.3 | 0.0 | 85.7 | 33.3 | 100.0 |
| SAE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PK: AUC0-tau of tirzepatide was reported.
| nanogram *hour per milliliter (ng*h/mL) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide | 105000 ± 33100 | 80800 ± 9580 | 156000 ± 22500 |
PK: Cmax of tirzepatide
| nanograms per milliliter (ng/mL) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) |
|---|---|---|---|
| PK: Maximum Concentration (Cmax) of Tirzepatide | 884 ± 243 | 674 ± 63.8 | 1280 ± 194 |
Collected over Baseline Up To 14 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Placebo (BW >=50 kg) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 2: Placebo (BW <50 kg) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Cohort 3: Placebo (BW 40 to 60 kg) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/2 | 1/6 | 0/2 | 1/7 | 0/3 | 6/7 |
| NauseaGastrointestinal disorders | 0/2 | 3/6 | 0/2 | 2/7 | 0/3 | 5/7 |
| Abdominal painGastrointestinal disorders | 0/2 | 0/6 | 0/2 | 1/7 | 1/3 | 4/7 |
| Decreased appetiteMetabolism and nutrition disorders | 0/2 | 3/6 | 0/2 | 1/7 | 0/3 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 1/6 | 0/2 | 0/7 | 0/3 | 3/7 |
| ConstipationGastrointestinal disorders | 0/2 | 2/6 | 0/2 | 0/7 | 1/3 | 0/7 |
| PyrexiaGeneral disorders | 0/2 | 0/6 | 0/2 | 1/7 | 1/3 | 0/7 |
| PneumoniaInfections and infestations | 0/2 | 0/6 | 0/2 | 0/7 | 1/3 | 0/7 |
| HeadacheNervous system disorders | 0/2 | 0/6 | 0/2 | 1/7 | 1/3 | 0/7 |
| DyspepsiaGastrointestinal disorders | 0/2 | 0/6 | 0/2 | 0/7 | 0/3 | 1/7 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 2 | 6 | 2 | 7 | 3 | 7 | 27 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | 2 | 5 | 2 | 4 | 17 |
| Male | 1 | 3 | 0 | 2 | 1 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 2 | 0 | 2 | 5 |
| Not Hispanic or Latino | 2 | 5 | 2 | 5 | 3 | 5 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 2 | 2 | 1 | 4 | 14 |
| White | 1 | 2 | 0 | 5 | 2 | 3 | 13 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Placebo (BW >=50 kg) | Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg) | Cohort 2: Placebo (BW <50 kg) | Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg) | Cohort 3: Placebo (BW 40 to 60 kg) | Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg) | Total |
|---|---|---|---|---|---|---|---|
| United States | 2 | 6 | 2 | 7 | 3 | 7 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Jan 2025, 23 months.
Results were first posted in Aug 2025, 7 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 23 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide